FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

FDA Accepts Application for Bristol-Myers Squibb and bluebird bio's Multiple Myeloma CAR-T Therapy

The Food and Drug Administration's acceptance means it will issue a go/no-go decision on ide-cel in March 2021.